Free Trial
NASDAQ:XAIR

Beyond Air Q4 2025 Earnings Report

Beyond Air logo
$0.19 0.00 (0.00%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.19 +0.00 (+1.05%)
As of 05:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beyond Air EPS Results

Actual EPS
N/A
Consensus EPS
-$0.14
Beat/Miss
N/A
One Year Ago EPS
N/A

Beyond Air Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.39 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Beyond Air Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Tuesday, June 17, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Beyond Air Earnings Headlines

Beyond Air granted U.S. patent for gaseous nitric oxide delivery
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Beyond Air Gets Patent for Lung Infection Treatment
See More Beyond Air Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beyond Air? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beyond Air and other key companies, straight to your email.

About Beyond Air

Beyond Air (NASDAQ:XAIR) operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

View Beyond Air Profile

More Earnings Resources from MarketBeat